Cargando…

Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells

INTRODUCTION: Inhibitors of cyclo-oxygenase (COX)-2 are being extensively studied as anticancer agents. In the present study we evaluated the mechanisms by which a highly selective COX-2 inhibitor, celecoxib, affects tumor growth of two differentially invasive human breast cancer cell lines. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Basu, Gargi D, Pathangey, Latha B, Tinder, Teresa L, Gendler, Sandra J, Mukherjee, Pinku
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1175053/ https://www.ncbi.nlm.nih.gov/pubmed/15987447 http://dx.doi.org/10.1186/bcr1019

Ejemplares similares

Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer
por: Roy, Lopamudra Das, et al.
Publicado: (2011)

Breast cancer-associated metastasis is significantly increased in a model of autoimmune arthritis
por: Das Roy, Lopamudra, et al.
Publicado: (2009)

Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes
por: Pathangey, Latha B., et al.
Publicado: (2016)

MUC1 Regulates PDGFA Expression During Pancreatic Cancer Progression
por: Sahraei, Mahnaz, et al.
Publicado: (2012)

Cyclooxygenase-1-selective inhibitor SC-560
por: Long, Sihui, et al.
Publicado: (2009)

First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]
por: Wittenberg, Ralf H, et al.
Publicado: (2006)

MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition
por: Roy, Lopamudra Das, et al.
Publicado: (2010)

Multipeptide stimulated PBMCs generate T(EM)/T(CM) for adoptive cell therapy in multiple myeloma
por: Vardam-Kaur, Trupti, et al.
Publicado: (2021)

Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer
por: Connolly, E M, et al.
Publicado: (2002)

Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens
por: Pathangey, Latha B., et al.
Publicado: (2016)

Comparative QSAR analysis of cyclo-oxygenase2 inhibiting drugs
por: Mohanapriya, Arumugam, et al.
Publicado: (2012)

Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk
por: Moore, R Andrew, et al.
Publicado: (2007)

Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage
por: Mirabito Colafella, Katrina M., et al.
Publicado: (2022)

Cyclin D1 Expression and the Inhibitory Effect of Celecoxib on Ovarian Tumor Growth in Vivo
por: Li, Wei, et al.
Publicado: (2010)

Inhibitory effect of celecoxib on agomelatine metabolism in vitro and in vivo
por: He, Jiayang, et al.
Publicado: (2018)

Use of Cyclo-Oxygenase Inhibitors Is Not Associated with Clinical Relapse in Inflammatory Bowel Disease: A Case-Control Study
por: Hensley, Abigail, et al.
Publicado: (2015)

Cyclo-Oxygenase (COX) Inhibitors and Cardiovascular Risk: Are Non-Steroidal Anti-Inflammatory Drugs Really Anti-Inflammatory?
por: Khan, Shanzana, et al.
Publicado: (2019)

The in vitro free radical scavenging activity of tenidap, a new dual cyclo-oxygenase and 5-1ipoxygenase inhibitor
por: Lau, C. S., et al.
Publicado: (1992)

Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis
por: Geusens, Piet, et al.
Publicado: (2008)

Inhibition of cyclo-oxygenase 2 reduces tumor metastasis and inflammatory signaling during blockade of vascular endothelial growth factor
por: Fisher, Jason C, et al.
Publicado: (2011)

Specific desensitization of the canine renal vasculature to angiotensin II despite cyclo-oxygenase inhibition.
por: Meggs, L. G., et al.
Publicado: (1985)

Characterisation of metabolites of the putative cancer chemopreventive agent quercetin and their effect on cyclo-oxygenase activity
por: Jones, D J L, et al.
Publicado: (2004)

Mastocytosis presenting with mast cell‐mediator release‐associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features
por: Rama, Tiago Azenha, et al.
Publicado: (2022)

Celecoxib: a selective cyclooxygenase-2 inhibitor
por: Gandelman, M
Publicado: (2003)

Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer
por: Wang, Shang-Jui, et al.
Publicado: (2020)

Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer
por: Leung, W K, et al.
Publicado: (2001)

The association between cyclo-oxygenase-2 expression and cell proliferation and angiogenesis in human breast cancer
por: Kirkpatrick, K, et al.
Publicado: (2001)

Cyclo-Oxygenase 2 Modulates Chemoresistance in Breast Cancer Cells Involving NF-κB
por: Zatelli, Maria Chiara, et al.
Publicado: (2009)

A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells
por: Basu, Gargi D, et al.
Publicado: (2006)

Vascular Endothelial Growth Factor Receptor-2 Couples Cyclo-Oxygenase-2 with Pro-Angiogenic Actions of Leptin on Human Endothelial Cells
por: Garonna, Elena, et al.
Publicado: (2011)

Cytokinesis-block micronucleus assay of celecoxib and celecoxib derivatives
por: Reimann, Hauke, et al.
Publicado: (2020)

Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo
por: Pyrko, Peter, et al.
Publicado: (2006)

Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells.
por: Tjandrawinata, R. R., et al.
Publicado: (1997)

The localization of cyclo-oxygenase immuno-reactivity (COX I-IR) to the urothelium and to interstitial cells in the bladder wall
por: de Jongh, R, et al.
Publicado: (2009)

Correction: Vascular Endothelial Growth Factor Receptor-2 Couples Cyclo-Oxygenase-2 with Pro-Angiogenic Actions of Leptin on Human Endothelial Cells
por: Garonna, Elena, et al.
Publicado: (2019)

Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis
por: Li, Mengtao, et al.
Publicado: (2020)

Impairment of Cyclo-oxygenase-2 Function Results in Abnormal Growth Plate Development and Bone Microarchitecture but Does Not Affect Longitudinal Growth of the Long Bones in Skeletally Immature Mice
por: Caron, Marjolein M. J., et al.
Publicado: (2019)

Multifocal Fixed Drug Eruption with COX-2 Inhibitor-Celecoxib
por: Chugh, Shikha, et al.
Publicado: (2013)

Cyclo-oxygenase 2, a putative mediator of vessel remodeling, is expressed in the brain AVM vessels and associates with inflammation
por: Keränen, Sara, et al.
Publicado: (2021)

Correction: Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fliclmtctmphck9mtckvilvn01